BIOLASE, Inc to Report Third Quarter 2022 Results on November 10, 2022
BIOLASE, Inc. (NASDAQ: BIOL) will announce its third quarter 2022 financial results on November 10, 2022, after U.S. markets close. A conference call is scheduled for the same day at 4:30 p.m. ET, where the company will discuss the results and ongoing developments. For participation, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally, using earnings code 720380. Biolase's innovative dental laser systems are instrumental in enhancing dental procedures worldwide.
- None.
- None.
LAKE FOREST, Calif., Oct. 27, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release third quarter 2022 financial and operating results on Thursday, November 10, 2022 after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.
To access the live call, dial 888-506-0062 (U.S.) or +1 973-528-0011 (International) and provide the following earnings code: 720380.
A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay dial 877-481-4010 or +1 919-882-2331 (International) and enter replay passcode: 46951.
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Contacts:
EVC Group, Inc.
Michael Polyviou/Todd Kehrli
(732) 232-6914
mpolyviou@evcgroup.com; tkehrli@evcgroup.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-inc-to-report-third-quarter-2022-results-on-november-10-2022-301660818.html
SOURCE BIOLASE, Inc.
FAQ
When will BIOLASE report its third quarter 2022 financial results?
What time is the BIOLASE conference call scheduled for?
How can I access the BIOLASE earnings conference call?
Where can I find the archived webcast of BIOLASE's conference call?
What is the focus of BIOLASE as a company?
